<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846716</url>
  </required_header>
  <id_info>
    <org_study_id>2008.9.18 ver2-4</org_study_id>
    <nct_id>NCT00846716</nct_id>
  </id_info>
  <brief_title>Shiga Progression of Diabetes, Nephropathy and Retinopathy</brief_title>
  <acronym>SHIP-DINER</acronym>
  <official_title>Exploratory Study to Investigate the Suppressive Effect of Oral Anti-Diabetic Drug (TZD) on Progression of Diabetic Nephropathy on</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiga University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kanazawa Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagahama Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagahama City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kohka Public Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Okamoto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Omihachiman COmmunity Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yasu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Toyosato Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ako City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Horide Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kawabata Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seta Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shiga Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NTT West Osaka Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hyogo prefectural Amagasaki Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tomita Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sawada Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Social Insurance Shiga Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shiga University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether the oral anti-diabetic drug, Thiazolidine
      (TZD) is effective in suppression of onset or progressin of diabetic nephropathy in Japanese
      type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2. Outcome measures:

        1. Primary endpoint Onset or progression of diabetic nephropathy

        2. Secondary endpoints (1)Progression of diabetes mellitus (2)Change in HbA1c (3)Change in
           albumin-creatinine ratio (4)Change in GFR (5)CHange in cystatin C
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset and progression of diabetic nephropathy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of diabetes mellitus change from the baseline in HbA1c change from the baseline in albumine/creatinine ratio change from the baseline in cystatin C onset and progression of diabetic retinopathy safety assessment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pioglitazone add on to SU or biguanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SU or Biguanide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone add on to SU or biguanide</intervention_name>
    <description>As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.</description>
    <arm_group_label>Pioglitazone add on to SU or biguanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU or Biguanide</intervention_name>
    <description>As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.</description>
    <arm_group_label>SU or Biguanide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus

          -  Less than 8.0% in HbA1c

          -  Less than 300 mg/g Cr of urinary albumine level

          -  Concomitant therapy with SU and/or Biguanide

          -  Untreated hypertension and hypertension treated with ARB or ACEI

        Exclusion Criteria:

          -  History of heart failure and concomitant heart failure

          -  History of administration of TZD agent

          -  Severe hepatic dysfunction with more than 3 times higher than upper limit of normal
             range of GOT, GPT or rGPT

          -  Severe renal dysfunction with more than 2.5 of Cr

          -  History of AE with TZD agent

          -  Insulin treatment

          -  Concomitant urinary track infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atsunori Kashiwagi, PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Tsukiwa-machi, Seta, Otsu, Shiga, Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiroshi Maegawa, PhD</last_name>
    <phone>+81-77-548-2222</phone>
    <email>maegawa@belle.shiga-med.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Takashi Uzu, PhD</last_name>
    <phone>+81-77-548-2222</phone>
    <email>tuzu@belle.shiga-med.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shiga University of Medical Science</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Maegawa, PhD</last_name>
      <phone>+81-77-548-2222</phone>
      <email>maegawa@belle.shiga-med.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Takashi Uzu, PhD</last_name>
      <phone>+81-77-548-2222</phone>
      <email>tuzu@belle.shiga-med.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Yoshihiko Nishio, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takashi Uzu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masato Ohji, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Osamu Sawada, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daisuke Koya, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>February 18, 2009</last_update_submitted>
  <last_update_submitted_qc>February 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Atsunori Kashiwagi</name_title>
    <organization>Shiga University of Medical Science</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>pioglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Biguanides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

